In the midst of a global pandemic, Pfizer, under the leadership of its chief digital and technology officer Lidia Fonseca, achieved what was once thought impossible. The company, with the partnership of BioNTech, developed a COVID-19 vaccine in only 269 days, a process that traditionally would have taken 8 to 10 years. While prior research…
How Accenture and AWS are upgrading Merck’s IT and drug discovery R&D engine
Historically, the pharma sector has exhibited a degree of caution in adopting emerging technologies such as cloud computing and AI, given the sector’s stringent regulatory requirements, data security concerns, and the complexities involved in integrating new systems into legacy processes. The situation is beginning to shift considerably with the COVID-19 pandemic, in particular, acting as…
Eversana’s AWS alliance aims to cut red tape in pharma regulatory paperwork
In July, the life sciences services company Eversana revealed it was partnering with AWS to tap generative AI (gen AI) for pharma and other life science customers. It aimed to “pharmatize” gen AI, as the company put it then. Now, the company has revealed the first technology from that partnership – a regulatory review automation…
AWS expands collaborations with Amgen and Merck to advance AI in drug discovery and manufacturing
At its annual re:Invent event, Amazon Web Services (AWS) announced expanded alliances with two leading drug developers, Amgen and Merck, to create generative artificial intelligence (AI) technologies aimed at accelerating drug discovery and increasing efficiencies in manufacturing processes. Merck has been working with AWS and Accenture for several years whereas Amgen and AWS have collaborated…
Eversana partners with AWS to accelerate generative AI in pharma
Life sciences commercial services company Eversana is one of the latest to throw its hat into the generative AI ring. Tapping a partnership with Amazon Web Services (AWS), Everasana is focusing on developing generative AI technologies in the pharmaceutical industry. Also this month, the startup Synthetica Bio announced it would use generative AI to boost…
A deep dive into AWS’s strategy with generative AI and ML in life sciences
The AI market is witnessing meteoric growth, with projections hinting at a potentially staggering increase over the next decade. Against this backdrop of rapid AI evolution, we recently spoke with Tehsin Syed, general manager of AWS Health. Syed shared that Amazon Web Services (AWS) is seeing growing interest from Big Pharma firms. “Nine of the…
Working backwards: AWS’s strategy for pharma’s cloud-enabled transformation
The meteoric rise of the AI sector is hard to fathom. Projections from Precedence Research suggest that the global AI market could balloon by 2600% from 2022 to 2032, hitting $1.87 trillion — an annual growth rate of 39%. In pharma, AI and data science demand is surging though overall growth is sluggish. Despite advances…
The Brain Knowledge Platform aims to illumine the brain’s cellular universe
Despite substantial progress in brain research, our understanding of the human brain remains limited. “We really don’t understand the fine circuitry of the brain — even in a relatively simple organism like a mouse,” confessed Ed Lein, a senior investigator at the Allen Institute for Brain Science. But AI in neuroscience research promises to change…
AWS and pharma heavyweights join forces on AI-based drug discovery lab
The goal of using artificial intelligence to transform drug discovery and development may not be novel. But a new alliance is unique in both the stature of companies belonging to it and its choice of an innovation model. Big Pharma firms AstraZeneca (LON:AZN), Merck KGaA (ETR: MRK), Pfizer (NYSE:PFE) and Teva (NYSE:TEVA) will partner with Amazon…